麦斯莫医疗 2025年季度报告

company,” and “emerging growth company” in Rule12b-2 of the Exchange Act.Large accelerated☒AcceleratedfilerNon-accelerated filer☐Smallerreportingcompany ☐☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:ClassNumber of Shares Outstanding as ofMarch 29, 2025 Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 29,2025 and March 30, 2024 March 30, 2024Notes to Condensed Consolidated Financial Statements Management’s Discussion and Analysis of Financial Condition and Results of OperationsQuantitative and Qualitative Disclosures About Market Risk Net change in in retirement obligationsUnrealized (loss) gain on cash flow hedgesTotal comprehensive (loss) As of December 28, 2024, the non-healthcare consumer business remained part of the Company’s continuing operations.Subsequently, the sales process has progressed in early 2025, and as of March 29, 2025, the non-healthcare consumer business has been classified as held-for-sale, and reported as discontinued operations. For additional information with respect to the non-healthcareconsumer business separation and discontinued operations of this business, please see Note 18, “Discontinued Operations”. On May 6,2025, the Company announced that it entered into a definitive agreement with HARMAN International, a wholly-owned subsidiary ofSamsung Electronics., Ltd., to sell its non-healthcare business. See Note 26, “Subsequent Events” for additional information. The terms “the Company” and “Masimo” refer to Masimo Corporation and, where applicable, its consolidated subsidiaries.2. Summary of Significant Accounting Policies the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statementsprepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensedor omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, including normalrecurring accruals, necessary to present fairly the Company’s condensed consolidated financial statements. The accompanyingcondensed consolidated balance sheet as of December28, 2024 was derived from the Company’s audited consolidated financialstatements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the auditedconsolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year endedDecember28, 2024 (fiscal year 2024), filed with the SEC on February25, 2025. The results for the three months ended March29, Fiscal Periods includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter.The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2025 is a 53 week fiscal year ending January3, 2026. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted. ReclassificationsCertain amounts for the current and comparative periods in the accompanying condensed consolidated financial statements have beenreclassified to conform to the discontinued operations presentation, including certain balance sheets, statements of operations,statements of comprehensive (loss) income, and statements stockholders’ equity, and statements of cash flows accounts in theconsolidated financial statements for the year ended December28, 2024, please see Note 18, “Discontinued Operations”. Use of Estimates assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates ofthe financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligationwithin a contract, inventory valuation, valuation of the Company’s equity awards, impairment of long-lived assets, intangible assetsand goodwill; derivative and equity instruments, deferred taxes and any associated valuation allowances, deferred revenue, accountingfor pensions, uncertain income tax positions, litigation costs, and related accruals.See Note 24, “Commitments and Contingencies” for Assets Held-For-Sale and Discontinued